Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset - HMS LINCS Database

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells	Antibodies

<
<<
Previous
Page 1 of 370
Next
>>
>
1 to 25 of 9248 records
per page:

Cell	Clinical Subtype	Transcriptional Subtype	Small Molecule	Antibody	Perturbagen Target	Perturbagen Class	Biological Replicate ID	Conc Unit	GR50	GEC50	GRmax	GRinf	GR Hill Coefficient	GR_AOC	GR r2	Nominal Division Rate
184A1	NM	Basal	(Z)-4-Hydroxytamoxifen		ESR1		9047.132	uM	inf	inf	0.4055	0.4055	0.0000	0.2074	0.3073	0.6985
184A1	NM	Basal	17-AAG		HSP90	HSP90	9047.037	uM	0.00930	0.01282	-0.9826	-0.6989	2.7212	1.1760	0.9539	0.5262
184A1	NM	Basal	5-DFUR		TYMS	TYMS	12509.143	uM	228.63720	1000.00000	-0.2404	-0.6424	0.5600	0.2642	0.9697	1.3392
184A1	NM	Basal	5-FU		TYMS	TYMS	9047.017	uM	48.1950	95.9710	-0.8459	-0.8556	1.4480	0.8094	0.9747	0.8440
184A1	NM	Basal	Afatinib		EGFR/HER2	ErbB	12509.165	uM	0.02251	0.33740	-0.9088	-1.0000	0.4058	0.8284	0.9307	1.5022
184A1	NM	Basal	AG1024		IGF1R	RTK	5894.066	uM	0.20895	0.19857	0.0442	0.1124	5.0000	0.3444	0.9895	1.5027
184A1	NM	Basal	AG1024		IGF1R	RTK	5895.066	uM	0.19048	0.25224	-0.2007	-0.1853	1.1224	0.4351	0.9959	1.1612
184A1	NM	Basal	AS-252424		PI3K	PI3K	12509.165	uM	4.22040	9.57840	-0.0901	-0.4857	0.8281	0.1987	0.9843	1.5022
184A1	NM	Basal	Baicalein		Lipoxygenase	Metabolism	5895.073	uM	inf	35.38250	0.5990	0.5817	2.0246	0.0235	0.9408	1.4431
184A1	NM	Basal	Bortezomib		Proteasome	Proteasome	5895.074	uM	0.02162	0.11251	-0.8342	-0.8244	0.5906	1.0107	0.9534	1.1218
184A1	NM	Basal	Bortezomib		Proteasome	Proteasome	5895.074	uM	0.02162	0.11251	-0.8342	-0.8244	0.5906	1.0107	0.9534	1.1218
184A1	NM	Basal	Bortezomib		Proteasome	Proteasome	5894.074	uM	0.03715	0.13270	-0.6899	-0.6765	0.6722	0.9059	0.9559	1.4541
184A1	NM	Basal	Bortezomib		Proteasome	Proteasome	5894.074	uM	0.03715	0.13270	-0.6899	-0.6765	0.6722	0.9059	0.9559	1.4541
184A1	NM	Basal	Bosutinib		Src	nRTK	12509.17	uM	0.45547	0.47009	-0.0739	-0.0269	1.6575	0.3664	0.9494	1.3955
184A1	NM	Basal	Carboplatin		DNA cross-linker	DNA cross-linker	9047.011	uM	9.5630	14.41690	-0.9873	-0.8900	2.4907	0.7356	0.9439	0.6293
184A1	NM	Basal	Carboplatin		DNA cross-linker	DNA cross-linker	10002.021	uM	13.72870	19.0030	-0.8276	-0.7818	2.8956	0.6151	0.9925	0.7195
184A1	NM	Basal		Cetuximab	EGFR	ErbB	7787.018	uM	inf	inf	0.4652	0.4652	0.0000	0.3838	-0.0013	0.3791
184A1	NM	Basal		Cetuximab	EGFR	ErbB	9047.026	uM	0.00360	0.01403	-0.2605	-0.4617	0.4805	0.4918	0.8777	0.5972
184A1	NM	Basal	CGC-11047		Polyamine analogue		10002.034	uM	242.78660	399.08510	-0.9907	-1.0000	2.2105	0.6269	0.7996	0.6736
184A1	NM	Basal	CGC-11047		Polyamine analogue		9047.026	uM	5.67110	70.62780	-0.9997	-1.0000	0.4356	0.7516	0.8174	0.5972
184A1	NM	Basal	CGC-11047		Polyamine analogue		7787.018	uM	839.83530	1000.00000	-0.8398	-0.6967	5.0000	0.2577	0.8874	0.3791
184A1	NM	Basal	Cisplatin		DNA cross-linker	DNA cross-linker	9047.017	uM	2.85670	3.92150	-0.9940	-0.8307	3.0896	0.5793	0.9882	0.8440
184A1	NM	Basal	Cisplatin		DNA cross-linker	DNA cross-linker	10002.021	uM	2.61470	4.77760	-0.9719	-0.9559	1.7730	0.6305	0.9959	0.7195
184A1	NM	Basal	CPT-11		TOP1	TOP	9047.121	uM	3.33380	6.76440	-0.6694	-0.7837	1.3326	0.4789	0.9103	0.7949
184A1	NM	Basal	CPT-11		TOP1	TOP	10002.034	uM	3.43020	4.22870	-0.9255	-0.9233	4.9992	0.4247	0.9962	0.6736

<
<<
Previous
Page 1 of 370
Next
>>
>
1 to 25 of 9248 records
per page:

HMS LINCS Project

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)